Topics

Clinical Trials About "Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine" RSS

02:10 EDT 2nd April 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine" on BioPortfolio

We have published hundreds of Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine news stories on BioPortfolio along with dozens of Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine Clinical Trials and PubMed Articles about Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine Companies in our database. You can also find out about relevant Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine Drugs and Medications on this site too.

Showing "Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine" Clinical Trials 1–25 of 63,000+

Extremely Relevant

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.


An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

Safety, Tolerability & Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.


Safety and Efficacy of Nerivio™ for the Acute Treatment of Migraine in Adolescents

Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. This is a prospective, single arm, open label, multicenter trial of the safety and efficacy ...

Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain

Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to that of a sham control treatment.

Efficacy and Safety of Nerivio™, a Remote Electrical Neuromodulation Device, for Acute Treatment of Migraine in People With Chronic Migraine: an Open Label, Single Arm, Multicenter Study

This study is intended to evaluate the efficacy and safety of Nerivio, an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine, for the acute treatment of migraine in people with chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The study duration consists of a 4 weeks of active treatment ...

An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the treatment of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safe...

A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.

Study of Low-level Laser Therapy in the Acute Treatment of Migraine

This study evaluates the treatment of migraine pain using low energy laser light to quench migraine signals issuing from the sphenopalatine ganglion (SPG).

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

This is a prospective, randomized, open-label study in subjects with migraine who have completed CoLucid Phase 3 study, COL MIG 301 or COL MIG-302. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.

Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine

The study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine

Acute Treatment of Migraine With the Cefaly® Device

The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients. The patients will be applied either an active or placebo external neurostimulation for 1 hour during a migraine attack, and will report the pain on a visual analog scale before and after the treatment.

Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine

The purpose of this migraine prevention study is to evaluate the efficacy and safety of AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and compared to a baseline period as measured by a reduction in the number of migraine days.

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

This study will be conducted to evaluate the safety and efficacy of sumatriptan nasal powder (AVP-825) compared to placebo in the acute treatment of migraine in adolescent participants, 12 through 17 years of age.

Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department

Migraine is a chronic and sometimes progressive disorder, characterized by headache, recurrent episodes, and other associated symptoms. Migraine is the most common cause of headache among patients who applied to emergency services. The purpose of the investigators is to compare the efficacy of oral paracetamol and zolmitriptan in the treatment of acute migraine headache in an emergency department.

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.

A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents

The purpose of this study is to evaluate the efficacy and safety of a range of doses of oral sumatriptan for the acute treatment of migraine in children ages 10 to 17.

Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine

Study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.

A Randomized, Double-Blinded, Placebo-Controlled, Cross Over Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

The purpose of this study is to see if Timolol 0.5% ophthalmic solution (Timolol eye drops) are a safe and effective treatment for acute migraine headaches.

Relevant

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

This is a prospective randomized, double-blind, placebo-controlled study in subjects with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

BI 44370 TA in Acute Migraine Attack

The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared to placebo and an active comparator.

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity. Qualified subjects will receive study medication for up to twelve months for the treatment of multiple migraine attacks. Using the eDiary to confirm they are experiencing a qualified migraine, subjects will self-administer the patches and respond to questions in the eDiary post treatment administration.


More From BioPortfolio on "Clinical Efficacy Safety Ubrogepant Acute Treatment Migraine"

Quick Search